Virobay Facts

2014 – Virobay appoints Thomas J. Dietz, Ph.D. to the Virobay Board of Directors more

2013 – Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain more

2013 – Virobay and LEO Pharma initiate a Phase 1 Trial of VBY-891, a compound intended for oral treatment of psoriasis more

2012 – Virobay's Cathepsin S selected as one of the Top 10 Anti-Inflammatory/Autoimmune Projects to Watch more

2012 – LEO Pharma A/S has entered into a multi-million dollar collaboration with Virobay Inc. to develop an oral treatment for psoriasis more

2010 – Virobay closes Series B financing

2008 – Virobay assets solve the chemical challenge of cathepsin inhibitor design; multiple development candidates are poised for Phase I

2007 – In-licensed cathepsin protease inhibitor assets

2007 – Filed IND and initiated Phase I trial with lead protease inhibitor as an oral treatment for Hepatitis C

2006 – Founded as a protease inhibitor drug discovery and development company

more

Welcome to Virobay, leaders in protease inhibitor design.

At Virobay we are developing protease inhibitors for the treatment of autoimmune diseases, neuropathic pain, liver diseases and cancer.

Our virtual model of drug discovery and development combines extensive in-house expertise with the resources of contract research and manufacturing facilities worldwide for cost effective and efficient development.

Our Pipeline

Virobay Pipeline Table
 
Research
 
Phase 0
(Clinical Candidate)
 
Phase 1
 
Phase 2
VBY-891
Psoriasis - LEO Pharma     X  
VBY-036
Pain     X  
Autoimmunity     X  
VBY-376
Fibrosis/NASH     X  
VBY-825
Fibrosis/PBC   X    
VBY-285
Autoimmunity   X    
Multiple Candidates
Cancer, Alzheimer's X